北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail
作者: Meng, Xue1; Wang, Jianhua2; Sun, Xindong1; Wang, Lvhua3; Ye, Ming4; Feng, Pingbo5; Zhu, Guangying6; Lu, You7; Han, Chun8; Zhu, Shuchai8; Liao, Zhongxing9; Yu, Jinming1
关键词: Esophagus carcinoma ; Cetuximab ; Chemoradiotherapy ; Phase II
刊名: RADIOTHERAPY AND ONCOLOGY
发表日期: 2013-11-01
DOI: 10.1016/j.radonc.2013.09.008
卷: 109, 期:2, 页:275-280
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Radiology, Nuclear Medicine & Medical Imaging
研究领域[WOS]: Oncology ; Radiology, Nuclear Medicine & Medical Imaging
关键词[WOS]: COLORECTAL-CANCER ; MUTATIONS ; TRIAL
英文摘要:

Background and purpose: This multicenter phase II trial investigated cetuximab combined with chemoradiotherapy in patients with esophageal squamous cell carcinoma (ESCC).

Material and methods: Eligible patients with non-resectable, locally-advanced ESCC received cetuximab 400 mg/m(2) loading dose on day 1; and on day 1 of the 2nd-7th weeks: cetuximab 250 mg/m(2), paclitaxel 45 mg/m(2), and cisplatin 20 mg/m(2), concurrent with 59.4 Gy/33 fractions of radiation therapy. Primary endpoint was clinical response rate. Secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, and KRAS status.

Results: Of 55 patients enrolled, 45 completed therapy. Forty-four patients had a clinical response: 29 complete response and 15 partial response. One-year PFS and OS of 45 evaluable patients were 84.23% and 93.33%, respectively, and 2-year PFS and OS were 74.87% and 80.00%, respectively. Non-hematologic adverse events were generally grade 1 or 2; primarily rash (92.7%), mucositis (45.5%), fatigue (41.8%), and nausea (38.2%). Grade 3 hematologic adverse events included neutropenia (32.7%) and anemia (1.8%). No KRAS mutations were identified in 50 evaluated samples.

Conclusions: Cetuximab can be safely administered with chemoradiotherapy to patients with locally-advanced ESCC and may improve clinical response rate. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

语种: 英语
WOS记录号: WOS:000329019900017
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/54110
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Zhengzhou Univ, Canc Hosp, Zhengzhou, Peoples R China
2.Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
3.Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
4.Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China
5.Chinese Acad Med Sci, Peking Union Med Coll, Canc Hosp, Beijing 100730, Peoples R China
6.Shanghai Jiao Tong Univ, Renji Hosp, Shanghai 200030, Peoples R China
7.Peking Univ, Sch Oncol, Beijing Canc Hosp, Beijing, Peoples R China
8.Sichuan Univ, West China Sch Med, West China Hosp, Chengdu 610064, Peoples R China
9.Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

Recommended Citation:
Meng, Xue,Wang, Jianhua,Sun, Xindong,et al. Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail[J]. RADIOTHERAPY AND ONCOLOGY,2013,109(2):275-280.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Meng, Xue]'s Articles
[Wang, Jianhua]'s Articles
[Sun, Xindong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Meng, Xue]‘s Articles
[Wang, Jianhua]‘s Articles
[Sun, Xindong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace